Apr 5 |
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 28 |
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 28 |
Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M
|
Mar 28 |
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
|
Feb 29 |
FDA clears Atara to begin Phase 1 study for lupus nephritis drug
|
Feb 29 |
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
|
Feb 28 |
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
|
Feb 14 |
Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma
|
Feb 14 |
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
|
Feb 6 |
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
|